• Finalisation of terms provides clear path to commercialise first product for bone regeneration
• Establishes imminent transition to commercialisation of Tetratherix's first product in 2026
• Construction begins of expanded, advanced manufacturing facility to meet anticipated global demand

Tetratherix Limited (ASX: TTX), a developer of novel clinical products based on its patented biomaterial polymer platform technology, has announced the execution of a global exclusive distribution and supply agreement with Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners. The agreement confirms Henry Schein as the Tetratherix distribution partner for Tegenix, the company's initial product for dental surgery. The agreement provides for initial and renewal terms, which are subject to agreed minimum purchases, and facilitates immediate access to Tegenix for Henry Schein's established global sales and distribution network. Tetratherix will strategically and deliberately launch its first commercial products based on a market seeding program, ensuring controlled early adoption, clinician engagement and robust post-market feedback. To meet this and anticipated future global demand, Tetratherix has commenced construction of its additional advanced manufacturing facility at its Alexandria campus in NSW. The facility is designed to further support the expanded production of Tetratherix's synthetic polymer platform products to meet anticipated global demand and is expected to be validated and operational in CY26.

Tetratherix anticipates the first commercial shipment of Tegenix to Henry Schein to occur in FY27 following FDA 510(k) clearance.